Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGC738 in advanced malignant solid tumors
NCT06728189Phase 1Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CGC-738 in Advanced Malignant Solid Neoplasm (AMSN), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Dose Limiting Toxicities at Day 28. Started Nov 2024; status: recruiting.
02
Drugs
CGC-738
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT06728189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06728189.